kdm5bb Antibody

What is KDM5B and why is it significant in epigenetic research?

KDM5B (also known as JARID1B, PLU1, or RBBP2H1) is a histone demethylase that specifically removes methyl groups from lysine 4 of histone H3 (H3K4), playing a central role in the histone code and epigenetic regulation. It functions as a transcriptional corepressor that demethylates trimethylated, dimethylated, and monomethylated H3K4, but does not affect H3K9 or H3K27 methylation states .

KDM5B's significance stems from its critical role in regulating gene expression by modifying chromatin structure. Dysregulation of KDM5B has been linked to various pathological conditions including cancer, neurodevelopmental disorders, and metabolic syndromes, making it a promising target for therapeutic interventions and a crucial focus in epigenetic research .

What are the known structural domains of KDM5B protein researchers should be aware of when selecting antibodies?

KDM5B is a multi-domain protein with several functional regions that researchers should consider when selecting antibodies:

When selecting antibodies, researchers should consider which domain they need to target based on their experimental questions. For instance, antibodies targeting the JmjC domain might be useful for studying catalytic activity, while those targeting the C-terminal region may be better for general detection .

How does KDM5B differ from other KDM5 family members in function and expression patterns?

KDM5B belongs to the KDM5 family of histone demethylases, which includes KDM5A, KDM5B, KDM5C, and KDM5D. While they share the ability to demethylate H3K4, they exhibit distinct functional roles and expression patterns:

KDM5B is unique in its role of recruiting SETDB1 to silence endogenous retroelements in a demethylase-independent manner, particularly in melanoma. This function appears distinct from other family members and contributes to its role in immune evasion .

What validation criteria should researchers apply when selecting a KDM5B antibody for specific applications?

Researchers should apply multiple validation criteria to ensure antibody specificity and performance:

• Knockout/Knockdown Validation: Use KDM5B knockout or knockdown cells as negative controls. Several commercial antibodies now offer "KO Validated" certification, providing higher confidence in specificity .

• Application-Specific Validation: Verify performance in your specific application (WB, IHC, ICC, etc.):

  • Western Blot: Confirm single band at expected molecular weight (160-180 kDa)

  • ICC/IF: Verify proper nuclear localization

  • IHC: Check for appropriate tissue distribution patterns

• Cross-Reactivity Testing: For mouse models, confirm whether the antibody cross-reacts between human and mouse KDM5B .

• Epitope Considerations: Select antibodies targeting specific regions based on experimental needs:

  • N-terminal epitopes for full-length protein detection

  • C-terminal epitopes (e.g., aa 1400-1500) for detecting specific isoforms

  • Central domains for analyzing functional regions

A validation workflow should include positive controls (cells known to express KDM5B, like BT-20 breast cancer or 293T cells) and negative controls (KDM5B knockout cells) .

How should researchers design experiments to distinguish between demethylase-dependent and demethylase-independent functions of KDM5B?

Distinguishing between the catalytic and non-catalytic functions of KDM5B requires a multi-faceted experimental approach:

• Parallel Genetic and Pharmacological Inhibition:

  • Genetic knockout/knockdown of KDM5B

  • Treatment with selective KDM5 inhibitors like CPI-455

  • Compare phenotypic outcomes between these approaches

• Rescue Experiments:

  • Reintroduce wild-type KDM5B to knockout cells

  • Reintroduce catalytically inactive KDM5B mutants

  • Compare ability to rescue phenotypes

• Readout Selection:

  • For demethylase-dependent functions: H3K4me3 levels by ChIP-seq or Western blot

  • For demethylase-independent functions: ERV expression by RT-qPCR

  • Protein complex formation by co-immunoprecipitation

Research has shown that genetic inactivation of KDM5B leads to increased ERV expression, while pharmacological inhibition with CPI-455 does not alter these transcripts, suggesting ERV suppression is independent of catalytic activity . By implementing this comparative approach, researchers can differentiate between these distinct functional modes.

What controls are essential when using KDM5B antibodies in chromatin immunoprecipitation (ChIP) experiments?

For reliable ChIP experiments with KDM5B antibodies, researchers should implement these essential controls:

• Input Control: Always process an input sample (pre-immunoprecipitation chromatin) through all steps to normalize for chromatin abundance variations.

• Negative Controls:

  • IgG control: Use the same host species IgG at equivalent concentration

  • KDM5B knockout/knockdown cells: Essential to confirm specificity

  • Non-target regions: Include genomic regions not expected to bind KDM5B

• Positive Controls:

  • Include known KDM5B binding loci (e.g., ERV regions, KRAB-ZNF genes)

  • Use cell lines with confirmed KDM5B expression (293T, BT-20)

• Antibody Validation:

  • Perform parallel ChIPs with two different KDM5B antibodies targeting distinct epitopes

  • Verify enrichment at expected sites (promoters, intergenic regions)

• Cross-Linking Assessment:

  • Optimize formaldehyde cross-linking conditions specifically for KDM5B

  • Test multiple cross-linking times to capture optimal protein-DNA interactions

According to chromatin accessibility studies, KDM5B binding is enriched at intergenic (48%) and intronic regions (39%), with significant overlap with SETDB1 and H3K9me3 peaks . These regions should be included as positive controls in experimental design.

How can researchers use KDM5B antibodies to investigate its role in endogenous retrovirus (ERV) silencing?

Investigating KDM5B's role in ERV silencing requires a multi-methodological approach using KDM5B antibodies:

• ChIP-seq Analysis:

  • Perform ChIP-seq with KDM5B antibodies to identify direct binding at ERV loci

  • Compare binding patterns with SETDB1 and H3K9me3 marks

  • Analyze data for enrichment at specific ERV families (MMVL30, ERV3-1, ERVW, HERVE, HERVF)

• Co-Immunoprecipitation (Co-IP):

  • Use KDM5B antibodies for Co-IP followed by Western blot for SETDB1 and KAP1

  • Verify physical interaction between KDM5B and the KRAB-ZNF repressor complex

• KDM5B Depletion Studies with ERV Readouts:

  • Compare ERV expression in wild-type, KDM5B-knockout, and CPI-455-treated cells

  • Measure ERV transcripts using RT-qPCR for ERV3-1, ERVW, HERVE, and HERVF

  • Analyze resulting cytoplasmic dsRNA accumulation and interferon response

• Sequential ChIP (Re-ChIP):

  • Perform sequential ChIP for KDM5B followed by SETDB1 to identify co-occupied regions

  • Focus analysis on ERV genomic loci

Research has demonstrated that KDM5B associates with components of the KRAB-ZNF repressor complex (KAP1 and SETDB1), suggesting its role as a scaffold in recruiting these complexes to ERV regions . This scaffolding function appears to be independent of its demethylase activity, as pharmacological inhibition does not alter ERV expression patterns .

What methodological approaches can detect KDM5B interaction with transcriptional repressor complexes?

To investigate KDM5B's interactions with transcriptional repressor complexes, researchers should employ these methodological approaches:

• Co-Immunoprecipitation with Western Blot Analysis:

  • Immunoprecipitate KDM5B using validated antibodies

  • Probe western blots for components of:

    • KRAB-ZNF repressor complex: KAP1, SETDB1

    • NuRD complex: RBAP46, HDAC1, HDAC2, MTA1, MBD3

  • Use appropriate controls including IgG and knockout samples

• Proximity Ligation Assay (PLA):

  • Use KDM5B antibody paired with antibodies against potential interactors

  • Quantify interaction signals in different cellular compartments

  • Compare results between wildtype and KDM5B-depleted cells

• ChIP-seq Co-localization Analysis:

  • Perform parallel ChIP-seq for KDM5B and repressor complex components

  • Analyze overlapping binding sites genome-wide

  • Focus on regions showing significant overlap between KDM5B and SETDB1 peaks (reported 61.2% overlap)

• Mass Spectrometry-Based Interactome Analysis:

  • Immunoprecipitate KDM5B and identify interacting proteins by mass spectrometry

  • Compare interactome in different cellular contexts (cancer vs. normal)

  • Validate key interactions using directed approaches

Research has demonstrated that immunoprecipitation of HA-tagged KDM5A successfully pulls down components of both the KRAB-ZNF repressor complex (KAP1, SETDB1) and the NuRD complex, suggesting these interactions are likely conserved with KDM5B . The choice of lysis conditions is critical, as some interactions may be sensitive to detergent types and salt concentrations.

How can researchers investigate the impact of KDM5B on anti-tumor immunity using KDM5B antibodies?

Investigating KDM5B's impact on anti-tumor immunity requires integrating antibody-based techniques with functional immunological assays:

• Tumor Microenvironment Analysis:

  • Perform multiplex immunofluorescence with KDM5B antibodies alongside immune cell markers

  • Quantify KDM5B expression in correlation with immune infiltration patterns

  • Compare expression in responders vs. non-responders to immunotherapy

• Mechanistic Studies in Cell Lines and Mouse Models:

  • Generate KDM5B-depleted tumor cell lines using CRISPR/Cas9

  • Validate depletion using KDM5B antibodies in Western blot and immunofluorescence

  • Assess:

    • ERV expression (RT-qPCR)

    • Type I interferon signaling (pSTAT1, ISGs)

    • Tumor growth in immunocompetent vs. immunodeficient mice

• Immune Response Characterization:

  • Analyze immune infiltrates in KDM5B-depleted vs. control tumors by flow cytometry

  • Perform immune rechallenge experiments to assess memory formation

  • Combine KDM5B depletion with immune checkpoint blockade

• Cytosolic Nucleic Acid Sensing Pathway Analysis:

  • Use KDM5B antibodies to correlate KDM5B levels with:

    • Cytosolic dsRNA accumulation

    • cGAS-STING pathway activation

    • Downstream interferon response

Research has shown that KDM5B depletion induces robust adaptive immune responses and enhances responses to immune checkpoint blockade by de-repressing endogenous retroelements, activating cytosolic RNA and DNA sensing pathways, and triggering type I interferon responses . This mechanism appears distinct from KDM5C alterations, which correlate with markedly higher TMB levels and enhanced response to immune checkpoint inhibitors .

How should researchers address specificity concerns when KDM5B antibody produces unexpected banding patterns in Western blots?

When encountering unexpected banding patterns with KDM5B antibodies in Western blots, researchers should systematically troubleshoot using this approach:

• Validate Band Identity:

  • KDM5B should appear at approximately 160-180 kDa

  • Use positive controls (293T, BT-20, or MCF-7 cell lysates)

  • Include KDM5B knockout/knockdown samples as negative controls

  • If available, use multiple KDM5B antibodies targeting different epitopes

• Address Common Issues:

  • Lower bands: May represent degradation products or isoforms

    • Use freshly prepared samples with protease inhibitors

    • Try reduced sample heating time/temperature

  • Higher bands: Could indicate aggregation or post-translational modifications

    • Adjust reducing agent concentration

    • Consider analyzing phosphorylation or other modifications

• Optimization Strategies:

  • Try different blocking reagents (BSA vs. milk)

  • Optimize primary antibody concentration (typical range: 1:500-1:2000)

  • Adjust sample preparation conditions:

    • Lysis buffer composition

    • Denaturation temperature

    • Gel percentage

• Isoform Consideration:

  • Check antibody epitope against known KDM5B isoforms

  • Consider alternative splicing that may affect epitope presence

Western blotting data from scientific literature shows that KDM5B appears as a specific band at approximately 170 kDa in 293T human embryonic kidney cell lysates when probed with appropriately validated antibodies . Significant deviation from this pattern warrants careful validation and optimization.

What strategies can resolve inconsistent immunostaining patterns when using KDM5B antibodies in different cell types?

Resolving inconsistent immunostaining patterns with KDM5B antibodies across different cell types requires a systematic approach:

• Cell Type-Specific Optimization:

  • Adjust fixation methods for different cell types:

    • Paraformaldehyde (typically 4%) for adherent cells

    • Methanol for better nuclear antigen access

  • Optimize permeabilization based on cell type:

    • Triton X-100 concentration (0.1-0.5%)

    • Saponin for more gentle permeabilization

• Epitope Retrieval Assessment:

  • Test multiple antigen retrieval methods:

    • Heat-induced epitope retrieval (citrate or EDTA buffers)

    • Enzymatic retrieval methods

  • Optimize retrieval time and temperature

• Expression Level Considerations:

  • Adjust antibody concentration based on KDM5B expression level

  • For low expression: Increase concentration and use signal amplification systems

  • For high expression: Reduce concentration to prevent oversaturation

• Validation Strategies:

  • Confirm nuclear localization pattern (KDM5B is predominantly nuclear)

  • Use RNA expression data to predict relative protein levels across cell types

  • Employ siRNA knockdown controls in each cell type

Published immunofluorescence data shows KDM5B localizes to nuclei in BT-20 human breast cancer cells when detected with appropriately validated antibodies at 10 μg/mL . Significant deviation from nuclear localization or inconsistent staining between related cell types warrants additional validation steps.

How can researchers interpret contradictory results between genetic KDM5B knockout and pharmacological inhibition experiments?

When faced with contradictory results between genetic KDM5B knockout and pharmacological inhibition, researchers should consider these analytical frameworks:

• Mechanistic Distinction Analysis:

  • Genetic knockout eliminates both catalytic and scaffolding functions

  • Pharmacological inhibitors (e.g., CPI-455) typically target only catalytic activity

  • Compare specific readouts that distinguish these functions:

• Temporal Considerations:

  • Acute vs. chronic effects:

    • Acute degradation (e.g., dTAG system) may better approximate inhibitor effects

    • Stable knockout may allow compensatory mechanisms to develop

• Inhibitor-Specific Analysis:

  • Assess inhibitor specificity across KDM5 family members

  • Consider off-target effects at higher concentrations

  • Evaluate cellular penetration and target engagement

• Integrated Data Interpretation:

  • Use multi-omics approaches (RNA-seq, ChIP-seq, ATAC-seq) to map:

    • Transcriptional changes

    • Chromatin accessibility alterations

    • Histone modification patterns

Research shows that genetic inactivation of KDM5B leads to downregulation of KRAB-ZNF genes and increased ERV expression, while pharmacological inhibition does not reproduce these effects . This divergence highlights KDM5B's demethylase-independent functions in assembling repressive complexes. When designing therapeutic approaches, this distinction suggests that KDM5B degraders may prove more effective than catalytic inhibitors for modulating immune responses .

How can KDM5B antibodies be utilized to study its role in immune checkpoint inhibitor response prediction?

Utilizing KDM5B antibodies to investigate its potential as a predictor of immune checkpoint inhibitor response involves:

What are the methodological approaches to investigate KDM5B in the context of cancer stem cell maintenance?

To investigate KDM5B's role in cancer stem cell maintenance, researchers should employ these methodological approaches:

• Cancer Stem Cell Identification and Isolation:

  • Use KDM5B antibodies in flow cytometry or immunofluorescence alongside established cancer stem cell markers

  • Employ cell sorting to separate KDM5B-high and KDM5B-low populations

  • Analyze stemness properties:

    • Self-renewal (sphere formation assays)

    • Differentiation capacity

    • Tumor initiation potential in limiting dilution assays

• Functional Studies:

  • Perform KDM5B knockdown/knockout in cancer stem cell populations

  • Assess impact on:

    • Expression of stemness genes

    • Self-renewal capacity

    • Drug resistance profiles

    • Tumor initiating capacity

• Epigenetic Landscape Analysis:

  • ChIP-seq using KDM5B antibodies in stem vs. differentiated cells

  • Focus on stemness-related gene promoters and enhancers

  • Correlate with H3K4me3 patterns and gene expression

• Clinical Correlation Studies:

  • Analyze patient samples for KDM5B expression in tumor hierarchies

  • Correlate with treatment resistance, recurrence, and patient outcomes

KDM5B has been implicated in maintaining stemness properties in various cancers, with high expression associated with melanoma maintenance and drug resistance . Methodological rigor in distinguishing cancer stem cells from bulk populations is essential for meaningful results in this context.

How can researchers investigate the potential of KDM5B degraders versus inhibitors using antibody-based approaches?

Investigating the therapeutic potential of KDM5B degraders compared to catalytic inhibitors requires comprehensive antibody-based approaches:

• Target Engagement Assessment:

  • Monitor KDM5B protein levels by Western blot after treatment with:

    • Catalytic inhibitors (e.g., CPI-455)

    • Degraders (PROTACs or molecular glues)

  • Perform time-course and dose-response analyses to determine:

    • Degradation kinetics

    • Recovery time

    • Required exposure for efficacy

• Functional Readout Comparison:

  • Compare effects of inhibitors vs. degraders on:

    • H3K4 methylation status (catalytic function)

    • ERV expression (non-catalytic function)

    • Interferon response gene expression

    • Cancer cell viability and immune activation

• Mechanistic Investigation:

  • Use co-immunoprecipitation to assess disruption of KDM5B-containing complexes

  • Monitor localization changes using immunofluorescence

  • Perform ChIP-seq to track chromatin occupancy changes

• In Vivo Efficacy Assessment:

  • Treat tumor-bearing mice with inhibitors or degraders

  • Monitor:

    • Tumor growth kinetics

    • Immune infiltration

    • Response to combination with immune checkpoint blockade

  • Use immunohistochemistry to confirm target degradation in tissues

Research has shown that genetic ablation of KDM5B produces more robust phenotypes than catalytic inhibition, particularly in immune activation . This suggests that degraders targeting KDM5B protein may offer superior therapeutic efficacy compared to catalytic inhibitors alone, especially for enhancing anti-tumor immune responses. Development of KDM5B degraders represents a promising avenue for overcoming the limited efficacy of small molecule inhibitors observed in cancer treatment .